Indeed, extracellular survivin was consistently associated with the development and progression of joint damage in RA and also distinguished patients with a therapy-resistant disease, nonresponders to biological treatment and those with a low rate of disease remission[11,13,18,23]. This evidence concerns the gene BIRC5 and rheumatoid arthritis.